On February 4, 2025, Novo Nordisk A/S announced the conclusion of its share repurchase program initiated on November 11, 2024, where it repurchased 4,599,494 B shares for approximately DKK 3.14 billion in total from November 11, 2024, to February 3, 2025, part of a larger plan involving DKK 20 billion over 12 months.